Preclinical review finds CBD effects on nitric oxide vary by enzyme

Isoform-Selective and Context-Dependent Modulation of Nitric Oxide Synthase by Cannabidiol: A Mechanistic Review of Preclinical Evidence in Neurological and Neuropathic Disorders.

Journal of inflammation research β€’ β€’ Review β€’ Highly Relevant
πŸ€–

AI Summary

This narrative review asks how cannabidiol (CBD) affects the nitric oxide synthase (NOS) enzymes nNOS, iNOS, and eNOS. It draws mainly on preclinical evidence from cell and animal models, rather than reporting a new clinical study. Its strongest finding is that CBD can suppress excessive iNOS expression and nitric oxide production in neuroinflammatory conditions.

Effects on nNOS are mixed and depend on the biological context: CBD may reduce harmful excitotoxicity in some models, yet nNOS-derived signaling contributes to CBD-related pain relief in certain neuropathic pain models. Evidence for eNOS effects in the brain is preliminary. This abstract-based summary reflects a narrative review; the evidence described cannot establish clinical benefit, and the review identifies a need for clinical trials using relevant biomarkers.

πŸ’‘ Key Findings

1
The review identifies suppression of pathological iNOS expression and nitric oxide production as the strongest preclinical evidence for CBD in neuroinflammatory conditions.
High
80%
2
CBD's effects on nNOS are context-dependent: it may attenuate pathological excitotoxicity in some models, while nNOS signaling contributes to CBD-induced analgesia in certain neuropathic pain models.
Good
70%
3
Evidence for eNOS-mediated benefits in the brain is preliminary, with cerebrovascular effects requiring further investigation.
High
80%
4
The preclinical findings do not establish clinical efficacy; the review highlights the need for clinical trials with biomarkers to validate NOS-related effects.
High
90%

πŸ“„ Original Abstract

Nitric oxide (NO), produced by nitric oxide synthase (NOS) isoforms, plays a dual role in the central nervous system. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, has shown promise as a neuroprotective and anti-inflammatory agent. This narrative review examines the complex interactions between CBD and NOS isoforms, including neuronal (nNOS), inducible (iNOS), and endothelial (eNOS) variants, and discusses how these may contribute to its neuroprotective and analgesic properties. Preclinical evidence, primarily from cellular and animal models, indicates that CBD can reduce excessive NO production, particularly by inhibiting iNOS in neuroinflammatory conditions. However, the effects of CBD on nNOS are context-dependent and cannot be characterized simply as inhibitory: while CBD may attenuate pathological nNOS-mediated excitotoxicity in some models, nNOS-derived NO is also required for CBD-induced analgesia in certain neuropathic pain models, where nNOS activation and downstream NO signaling contribute to antinociception. The strongest preclinical evidence supports CBD-mediated suppression of pathological iNOS expression and NO production in neuroinflammatory conditions. The effects of CBD on nNOS are context-dependent and cannot be characterized simply as inhibitory: while CBD may attenuate pathological nNOS-mediated excitotoxicity in some models, nNOS-derived NO is also required for CBD-induced analgesia in certain neuropathic pain models, where nNOS activation and downstream NO signaling contribute to antinociception. Similarly, evidence for eNOS-mediated vascular benefits in the CNS remains preliminary and largely derived from peripheral studies, and cerebrovascular eNOS effects require further investigation. We review the potential therapeutic implications of these interactions in neurological conditions such as Alzheimer's disease, multiple sclerosis, depression, and neuropathic pain. The review also addresses antioxidant and anti-nitrosative benefits of CBD, pharmacokinetic challenges, and research gaps, including the need for clinical trials with biomarkers to validate NOS-related findings. By integrating molecular, preclinical, and translational perspectives, this review provides insights into the context-dependent and isoform-selective modulation of NOS by CBD, emphasizing that the strength of evidence varies by isoform, with iNOS and nNOS modulation being better established than eNOS-related effects.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.